Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MindBio Therapeutics Corp C.MBIO

MindBio Therapeutics Corp. is a biotech/biopharma company. It creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. It is focused on microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. It develops a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder. The underway are two Phase 2B trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. It invests in research that forms the basis for developing novel and clinically proven treatments.


CSE:MBIO - Post by User

Comment by Smokey1958on May 01, 2024 10:16pm
49 Views
Post# 36018680

RE:CEO

RE:CEOI'll add another of the following to the latest naysayer on CEO:

* liabilities will ALWAYS be higher than assets for a startup that has yet to make revenue.

Junior mining companies have liabilities that are 10s of millions higher than their assets. Until they actually mine their only asset of "worth" (?) is their stake and/or land holding. Almost everything else that is put into sampling, test sites and administration is a liability.

There are numerous investors including the government of NZ and public shareholders that have invested in MBIO. It takes money to carry out research before making money.

* As for why a foreign (Australian) company would list on a Canadian exchange ...it happens all the time. I don't know the reason but would speculate it's because there is a larger pool of investors ....including those living in the country south of us.

MBIO could just as easily go either way depending on the efficacy of their results. But if you're going to dump on the company does it not make sense that it's carried out with a modicum of rational thought and evidence.

GLTE ....waiting for continued positive research outcomes!!!
<< Previous
Bullboard Posts
Next >>